The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Health-related quality of life in stage III melanoma patients treated with neoadjuvant ipilimumab and nivolumab followed by index lymph node excision only, compared to therapeutic lymph node dissection: First results of the PRADO trial.
 
Noëlle Milena Jane Van den Heuvel
No Relationships to Disclose
 
Irene L.M. Reijers
No Relationships to Disclose
 
Elisa A. Rozeman
No Relationships to Disclose
 
Judith M. Versluis
No Relationships to Disclose
 
Katarzyna Józwiak
No Relationships to Disclose
 
Andrew Spillane
Honoraria - Stryker
 
Richard A. Scolyer
Consulting or Advisory Role - Merck Sharp & Dohme; Myriad Pharmaceuticals; NeraCare GmbH; Novartis
 
Thomas Pennington
No Relationships to Disclose
 
Robyn PM Saw
Honoraria - Merck Sharp & Dohme; Novartis
Consulting or Advisory Role - Merck Sharp & Dohme; Novartis
 
Maria Gonzalez
No Relationships to Disclose
 
Winan J. van Houdt
Consulting or Advisory Role - Amgen; Sanofi
Speakers' Bureau - Amgen
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - MSD
 
Willem M.C. Klop
Travel, Accommodations, Expenses - Roche
 
Michel W.J.M. Wouters
No Relationships to Disclose
 
Alexander M. Menzies
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; Roche
 
Alexander Christopher Jonathan Van Akkooi
Consulting or Advisory Role - 4SC (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); MSD Oncology (Inst); Novartis (Inst); Sanofi (Inst)
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Novartis
 
Lonneke V van de Poll-Franse
No Relationships to Disclose
 
Georgina V. Long
Honoraria - Bristol-Myers Squibb; Merck; Pierre Fabre
Consulting or Advisory Role - Aduro Biotech; Amgen; Array BioPharma; Bristol-Myers Squibb; GlaxoSmithKline UK Ltd.; Hexal; MERCK; Novartis; OncoSec; Pierre Fabre; Roche
 
Christian U. Blank
Stock and Other Ownership Interests - Forty Seven; Neon Therapeutics; Uniti Cars
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); GenMab (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst); Third Rock Ventures
Research Funding - Bristol-Myers Squibb (Inst); NanoString Technologies (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Annelies H. Boekhout
Research Funding - Bristol-Myers Squibb (Inst)